Abstract:Accurate detection of circulating tumor DNA (ctDNA) has the potential to guide personalized cancer therapy. DNA viruses such as Epstein-Barr virus (EBV) and human papillomavirus (HPV) are major oncologic drivers of nasopharyngeal cancer (NPC) and cervical cancer (CC), respectively, and provide a convenient etiological marker for measurement of ctDNA. Polymerase chain reaction (PCR)-based methods have been widely studied, but more accurate tests are needed. We hypothesized that a next generation sequencing (NGS) approach could outperform PCR-based methods for viral ctDNA detection. We developed a novel NGS method for viral ctDNA detection. Viral genome sequencing for EBV (EBV-seq) or HPV (HPV-seq) was achieved by hybrid capture NGS. Unique molecular identifiers were incorporated for accurate copy number quantification. We implemented a custom bioinformatics workflow to (1) quantify viral sequences, (2) report viral subtype, and (3) measure ctDNA fragment length. The lower limit of detection (LLOD) was compared with published PCR-based methods in cell line dilution series. To test performance on clinical samples, we applied EBV-seq to a cohort of 19 newly diagnosed EBV-associated NPC patients for whom the clinical EBV quantitative PCR test had provided a false negative result and to a control cohort of 20 healthy volunteers. We applied HPV-seq to 40 plasma samples from a cohort of 18 CC patients treated with chemoradiotherapy and to a control cohort of 5 healthy volunteers. The LLOD of EBV-Seq was ≤0.01 EBV genome-equivalents (GE), 100X lower than quantitative PCR. The LLOD of HPV-seq was ≤0.2 HPV GE, 10X lower than digital PCR. For EBV-seq, 19/19 NPC patients had detectable ctDNA (sensitivity=100%, range=0.08-141 EBV GE); 10/20 controls had detectable ctDNA (specificity=50%, range=0.02-0.71 EBV GE). 17/19 (89%) patients, including 6/6 with stage I-II disease, had EBV-seq levels that were >20X above the highest level seen in the control cohort (i.e., 89% sensitivity with 100% specificity). For HPV-seq, 6/6 baseline CC samples, 10/17 (59%) end-of-treatment samples, 1/14 (7%) 3-month post-treatment samples, and 3/3 samples taken upon recurrence had positive HPV-seq results (sensitivity=100%, range=0.02-559 HPV GE) that were highly correlated with digital PCR (Pearson R=0.97) but with 60X higher signal than digital PCR; 0/5 controls had detectable ctDNA (specificity=100%). EBV-seq and HPV-seq were able to report viral subtype in 49/49 positive samples. Viral ctDNA was consistently shorter than non-cancer-derived plasma DNA (median difference=15bp). For DNA virus-associated cancers, viral genome NGS provides dramatically greater sensitivity than PCR-based methods and enables viral subtyping and ctDNA fragment length analysis. Further evaluation is warranted to test the clinical utility of ultrasensitive ctDNA detection using this approach.

Quantification of low-level Cytomegalovirus and Epstein-Barr virus DNAemia by digital PCR

Comparison of Real-Time PCR and Digital PCR for Detection of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma

Discordant detection of human cytomegalovirus DNA from peripheral blood mononuclear cells, granulocytes and plasma: correlation to viremia and HCMV infection

Monitoring human cytomegalovirus infection with nested PCR: comparison of positive rates in plasma and leukocytes and with quantitative PCR

Digital Quantification of Human Viral RNA and DNA Using a Self-Digitization Chip

Analytical and Clinical Performance of the NeuMoDxTM Platform for Cytomegalovirus and Epstein–Barr Virus Viral Load Testing

Viral Genome Sequencing for Ultrasensitive Detection of Circulating Tumor DNA

Highly precise measurement of HIV DNA by droplet digital PCR

Evaluation of Droplet Digital PCR Assay for the Diagnosis of Candidemia in Blood Samples

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment

Quantification of human papillomavirus cell-free DNA from low-volume blood plasma samples by digital PCR

Comparison of automated nucleic acid extraction methods for the detection of cytomegalovirus DNA in fluids and tissues

Quantitative PCR Determination of Human Cytomegalovirus in Blood Cells

Sensitive and Accurate Quantification of Enterovirus-D68 (EV-D68) Viral Loads Using Droplet Digital PCR (ddPCR)

Evaluation of Performance and Application of Three Nucleic Acid Extraction Methods for Quantification of Plasma Epstein-Barr Virus DNA

Analytical validation of the DropXpert S6 system for diagnosis of chronic myelocytic leukemia

Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR

Clinical application of Epstein-Barr virus DNA loads in Epstein-Barr virus-associated diseases: A cohort study

Rapid quantitation of cytomegalovirus DNA in whole blood by a new molecular assay based on automated sample preparation and real-time PCR

The potential advantages of digital PCR for clinical virology diagnostics